Generic Medicine Info
Indications and Dosage
Androgen deficiency, Infertility due to hypogonadism
Adult: Male: Initially, 75-100 mg daily in 3 or 4 divided doses for several mth. Maintenance: 50-75 mg daily in divided doses.
May be taken with or without food.
Current or history of hepatic tumours. Prostatic carcinoma.
Special Precautions
Not suitable for increasing muscular development and physical ability.
Adverse Reactions
Significant: Frequent or persistent erections.
Monitoring Parameters
Regularly monitor prostate status.
Description: Mesterolone supplements endogenous androgens w/ less inhibitory effect on intrinsic testicular function than testosterone and its derivatives.
Absorption: Rapidly and almost completely absorbed from the GI tract. Absolute bioavailability: Approx 3%. Time to peak plasma concentration: Approx 1.6 hr.
Distribution: Plasma protein binding: 98% (40% to albumin, 58% to sex hormone binding globulin).
Metabolism: Rapidly metabolised to 1α-methyl-androsterone, 1α-methyl-5α-androstane-3α, 17β-diol and other metabolites.
Excretion: Via urine (approx 77% as metabolites) and faeces (approx 13% as metabolites). Terminal half-life: 12-13 hr.
MIMS Class
Androgens & Related Synthetic Drugs
ATC Classification
G03BB01 - mesterolone ; Belongs to the class of 5-androstanon (3) derivative androgens used in androgenic hormone preparations.
Anon. Mesterolone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 26/07/2017.

Buckingham R (ed). Mesterolone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 26/07/2017.

Joint Formulary Committee. Mesterolone. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 26/07/2017.

Disclaimer: This information is independently developed by MIMS based on Mesterolone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
  • Proviron
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in